Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
11.38
-0.04 (-0.35%)
Oct 21, 2025, 4:00 PM EDT - Market closed
Delcath Systems Revenue
Delcath Systems had revenue of $24.16M in the quarter ending June 30, 2025, with 211.05% growth. This brings the company's revenue in the last twelve months to $70.24M, up 491.35% year-over-year. In the year 2024, Delcath Systems had annual revenue of $37.21M with 1,701.69% growth.
Revenue (ttm)
$70.24M
Revenue Growth
+491.35%
P/S Ratio
5.33
Revenue / Employee
$731,667
Employees
96
Market Cap
398.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.21M | 35.14M | 1,701.69% |
Dec 31, 2023 | 2.07M | -654.00K | -24.05% |
Dec 31, 2022 | 2.72M | -836.00K | -23.52% |
Dec 31, 2021 | 3.56M | 1.91M | 115.98% |
Dec 31, 2020 | 1.65M | 66.00K | 4.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DCTH News
- 7 hours ago - Delcath Systems to Host Third Quarter 2025 Earnings Call - Business Wire
- 23 hours ago - Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript - Seeking Alpha
- 1 day ago - Delcath: Large Upside With Limited Downside Risk - Seeking Alpha
- 2 days ago - Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results - Business Wire
- 3 days ago - Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint - Business Wire
- 4 weeks ago - Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress - Business Wire
- 6 weeks ago - Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Delcath Systems to Participate in Upcoming Investor Conferences - Business Wire